Merck Serono GmbH would like to inform you in agreement with the Federal Institute for Drugs and Medical Devices that a new formulation of Euthyrox® (levothyroxine) tablets will be available End of April/Beginning of May 2019. The re-formulated tablets offer improved stability of the active substance throughout the medicinal product’s shelf life and do not contain lactose, an excipient with known effect in patients with lactose intolerance. How levothyroxine is taken and monitored remains unchanged. Close monitoring of patients switching between tablets is recommended as thyroid imbalances can be triggered by the switch due to levothyroxine’s narrow therapeutic range.